Accedi

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the body over time. Calculating the free drug concentration in target organs involves a formula that factors in blood flow rate and the extent of drug binding to proteins.

Models of linear drug binding assume the unbound drug fraction remains constant, irrespective of the total drug concentration. This assumption simplifies the interpretation and application of the model. The term 'Clint' denotes an organ's efficiency in drug clearance. It represents the organ's inherent capacity to metabolize and eliminate drugs, a critical factor in drug distribution and effect.

Lastly, the mass balance for the drug in the blood pool provides a comprehensive analysis of drug distribution in all organs. It is an integral part of these models, highlighting the vital role of drug binding in the overall distribution process. Understanding these elements offers valuable insights into drug behavior within the body and contributes to more effective and precise drug administration.

Tags

Physiological Pharmacokinetic ModelsProtein BindingDrug DispositionDrug protein InteractionsDrug ConcentrationsDrug DosingEquilibrationFree Drug ConcentrationBlood Flow RateLinear Drug BindingUnbound Drug FractionClintOrgan EfficiencyDrug ClearanceMass BalanceDrug Distribution

Dal capitolo 7:

article

Now Playing

7.21 : Physiological Pharmacokinetic Models: Assumption with Protein Binding

Pharmacokinetic Models

20 Visualizzazioni

article

7.1 : Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Pharmacokinetic Models

53 Visualizzazioni

article

7.2 : Model Approaches for Pharmacokinetic Data: Compartment Models

Pharmacokinetic Models

51 Visualizzazioni

article

7.3 : One-Compartment Open Model for IV Bolus Administration: General Considerations

Pharmacokinetic Models

105 Visualizzazioni

article

7.4 : One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

Pharmacokinetic Models

95 Visualizzazioni

article

7.5 : One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

Pharmacokinetic Models

35 Visualizzazioni

article

7.6 : One-Compartment Model: IV Infusion

Pharmacokinetic Models

109 Visualizzazioni

article

7.7 : One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model

Pharmacokinetic Models

38 Visualizzazioni

article

7.8 : One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model

Pharmacokinetic Models

146 Visualizzazioni

article

7.9 : One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

Pharmacokinetic Models

212 Visualizzazioni

article

7.10 : One-Compartment Open Model: Urinary Excretion Data and Determination of k

Pharmacokinetic Models

63 Visualizzazioni

article

7.11 : Multicompartment Models: Overview

Pharmacokinetic Models

53 Visualizzazioni

article

7.12 : Two-Compartment Open Model: Overview

Pharmacokinetic Models

74 Visualizzazioni

article

7.13 : Two-Compartment Open Model: IV Bolus Administration

Pharmacokinetic Models

202 Visualizzazioni

article

7.14 : Two-Compartment Open Model: IV Infusion

Pharmacokinetic Models

140 Visualizzazioni

See More

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati